title: EMACO in high risk gestational trophoblast disease--the Australian experience. Gestational Trophoblast Subcommittee, Clinical Oncological Society of Australia.
abstract: Sixty-five patients with high-risk trophoblast disease have been treated with the EMACO combination split regimen therapy in the 10 year period, 1981 to 1990. Four patients died but the remaining 61 (94%) remain free of disease up to 10 years later. Toxicity was manageable in most cases with minimal delay in treatment from myelosuppression. EMACO is a well tolerated regimen with a high cure rate in patients with high-risk gestational trophoblast disease (GTD).
authors.affiliation: Royal Women's Hospital, Carlton, Victoria.
authors.forename: M
authors.initials: M
authors.lastname: Quinn
authors.forename: J
authors.initials: J
authors.lastname: Murray
authors.forename: M
authors.initials: M
authors.lastname: Friedlander
authors.forename: S
authors.initials: S
authors.lastname: Steigrad
authors.forename: S
authors.initials: S
authors.lastname: Khoo
authors.forename: D
authors.initials: D
authors.lastname: Marsden
authors.forename: I
authors.initials: I
authors.lastname: Hammond
authors.forename: T
authors.initials: T
authors.lastname: Jobling
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001315:Australia; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011247:Pregnancy; D012306:Risk; D014328:Trophoblastic Neoplasms / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate